Bristol CAR-T Death, Roche Drug Extends Survival — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Bristol Myers Squibb reported that one patient died after receiving its investigational CAR-T therapy in an early Phase 1 trial for multiple sclerosis.
- Bristol Myers Squibb said the patient developed motor symptoms that did not resolve with standard autoimmune treatments, then received a potent immunosuppressant and developed septic pneumonia before dying.
- Bristol Myers Squibb later said the patient had been treated for a series of other complications before the CAR-T therapy, confounding its ability to determine the root cause.
- Divarasib helped patients with metastatic non-small cell lung cancer live almost six months longer than two competitive medicines in a late-stage study.
- Divarasib fared better than similar drugs from Amgen and Bristol Myers Squibb in that study of previously treated patients whose tumors carried the KRAS G12C mutation.
Why it matters: For Roche and patients with previously treated KRAS G12C-mutated non-small cell lung cancer, divarasib’s nearly six-month survival edge over drugs from Amgen and Bristol Myers Squibb provides a direct late-stage comparison. The reported findings underpin its potential to become the treatment of choice for this molecularly defined cancer.
Ask SkimNews
